Inhibikase Therapeutics, Inc. (IKT)
NASDAQ: IKT · Real-Time Price · USD
1.660
+0.040 (2.47%)
At close: Oct 8, 2025, 4:00 PM EDT
1.680
+0.020 (1.20%)
After-hours: Oct 8, 2025, 7:32 PM EDT
Inhibikase Therapeutics Market Cap
Inhibikase Therapeutics has a market cap or net worth of $123.70 million as of October 8, 2025. Its market cap has increased by 1,281.03% in one year.
Market Cap
123.70M
Enterprise Value
34.21M
1-Year Change
1,281.03%
Ranking
Category
Stock Price
$1.66
Market Cap Chart
Since the IPO on December 23, 2020, Inhibikase Therapeutics's market cap has increased from $100.46M to $123.70M, an increase of 23.14%. That is a compound annual growth rate of 4.44%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Oct 7, 2025 | 120.72M | -44.72% |
| Dec 31, 2024 | 218.38M | 2,684.93% |
| Dec 29, 2023 | 7.84M | -37.83% |
| Dec 30, 2022 | 12.61M | -65.89% |
| Dec 31, 2021 | 36.98M | -46.68% |
| Dec 31, 2020 | 69.35M | -30.96% |
| Dec 23, 2020 | 100.46M | - |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Eli Lilly and Company | 758.63B |
| Johnson & Johnson | 453.15B |
| AbbVie | 406.64B |
| UnitedHealth Group | 324.93B |
| Novo Nordisk | 269.41B |
| AstraZeneca | 265.89B |
| Novartis AG | 257.47B |
| Abbott Laboratories | 232.77B |